Evidence map›Paper›PMID 30848917›Full record

ArticleMolecular pharmaceutics2019

Topography of Simulated Intestinal Equilibrium Solubility.

Claire Dunn, Jeremy Perrier, Ibrahim Khadra, Clive G Wilson, Gavin W Halbert

Open access · hybridAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2022
    Article
  3. Small scale in vitro method to determine a bioequivalent equilibrium solubility range for fasted human intestinal fluid.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Claire DunnStrathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , 161 Cathedral Street , Glasgow G4 0RE , United Kingdom.
Jeremy PerrierStrathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , 161 Cathedral Street , Glasgow G4 0RE , United Kingdom.
Ibrahim KhadraStrathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , 161 Cathedral Street , Glasgow G4 0RE , United Kingdom.
Clive G WilsonStrathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , 161 Cathedral Street , Glasgow G4 0RE , United Kingdom.
Gavin W HalbertStrathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , 161 Cathedral Street , Glasgow G4 0RE , United Kingdom.ORCID 0000-0001-8553-3647
University of Strathclyde · GB

Funding

Cancer Research UK 11526Cancer Research UK 20740Prostate Cancer UK PG12-27
6 · The paper itself

Abstract

Oral administration of a solid dosage form requires drug dissolution in the gastrointestinal tract before absorption. Solubility is a key factor controlling dissolution, and it is recognized that, within the intestinal tract, this is influenced by the luminal fluid pH, amphiphile content, and composition. Various simulated intestinal fluid recipes have been introduced to mimic this behavior and studied using a range of different experimental techniques. In this article, we have measured equilibrium solubility utilizing a novel four component mixture design (4CMD) with biorelevant amphiphiles (bile salt, phospholipid, oleate, and monoglyceride) within a matrix of three pH values (5, 6, and 7) and total amphiphile concentrations (11.7, 30.6, and 77.5 mM) to provide a topographical and statistical overview. Three poorly soluble drugs representing acidic (indomethacin), basic (carvedilol), and neutral (fenofibrate) categories have been studied. The macroscopic solubility behavior agrees with literature and exhibits an overall increasing solubility from low pH and total amphiphile concentration to high pH and total amphiphile concentration. Within the matrix, all three drugs display different topographies, which can be related to the statistical effect levels of the individual amphiphiles or amphiphile interactions on solubility. The study also identifies previously unreported three and four way factor interactions notably between bile salt, phospholipid, pH, and total amphiphile concentration. In addition, the results also reveal that solubility variability is linked to the number of amphiphiles and the respective ratios in the measurement fluid, with the minimum variation present in systems containing all four amphiphiles. The individual 4CMD experiments within the matrix can be linked to provide a possible intestinal solubility window for each drug that could be applied in PBPK modeling systems. Overall the approach provides a novel overview of intestinal solubility topography along with greater detail on the impact of the various factors studied; however, each matrix requires 351 individual solubility measurements. Further studies will be required to refine the experimental protocol in order the maximize information garnered while minimizing the number of measurements required.

Indexed as

Models, BiologicalAcid-Base EquilibriumAdministration, OralBile Acids and SaltsBody FluidsCarvedilolChemistry, PharmaceuticalDosage FormsDrug LiberationFenofibrateHumansHydrogen-Ion ConcentrationIndomethacinIntestinal AbsorptionIntestinal SecretionsMonoglyceridesBile Acids and SaltsCarvedilolDosage FormsFenofibrateIndomethacinMonoglyceridesPhospholipidsSurface-Active AgentsBiopharmaceutics Classification SystemFaSSIFFeSSIFfour component mixture designIVIVCpHsolubilitytotal amphiphile concentration

Identifiers

PMID30848917
PMCPMC6505523
OpenAlexW2921692650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.